PD-L1 Expression and Clinical Outcomes With Cabozantinib, Everolimus, and Sunitinib in Patients With Metastatic RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus and Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
Clin. Cancer Res 2019 Aug 01;[EPub Ahead of Print], A Flaifel, W Xie, DA Braun, M Ficial, Z Bakouny, AH Nassar, RB Jennings, B Escudier, DJ George, RJ Motzer, MJ Morris, T Powles, E Wang, Y Huang, GJ Freeman, TK Choueiri, S SignorettiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.